Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback